One-shot gene silencing therapy for chronic and life-threatening conditions

Benitec Biopharma’s DNA-directed RNA interference platform can generate single-application therapies to silence defective genes in a wide range of diseases whilst overcoming many of the limitations of short interfering RNA. To download the full article, please sign in.

Nov 05, 2015
1
Page of

Benitec Biopharma Ltd

Benitec Biopharma was founded in 1997 and has been publicly listed on the ASX since then. During the mid 2000's, Benitec was involved in a lengthy and ultimately successful patent litigation, which included defense of our platform technology patents. This action resulted in their being re-examined and re-issued in all jurisdictions by 2012. Benitec Biopharma is developing therapeutic agents in-house for use with human conditions of high prevalence and value. In addition, we out-license our proprietary technology to biotechnology and biopharma companies for use in non-core therapeutic areas, such as HIV/AIDS, Retinitis Pigmentosa, Huntington's Disease, and human cancer vaccines. We also licence the technology as a research agent and cross-license in other situations.

Comments are disabled